Contralateral upper tract urothelial carcinoma after nephroureterectomy: The predictive role of DNA methylation

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Zhang, Lei ^a   Xiong, Gengyan ^a   Fang, Dong ^a   Li, Xuesong ^a   Liu, Jin ^a   Ci, Weimin ^b   Zhao, Wei ^c   Singla, Nirmish ^d   He, Zhisong ^a   Zhou, Iqun ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Chinese Academy of Sciences   (China)

^c Department of Biochemistry and Molecular BiologyCancer Hospital of Peking University   (China)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Contralateral recurrence; Methylation; Predictors; Radical nephroureterectomy; Upper tract urothelial carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DNA METHYLATION; FEMALE; FOLLOW UP; GENE LOCUS; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEPHROURETERECTOMY; POLYMERASE CHAIN REACTION; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; RISK FACTOR; TRANSITIONAL CELL CARCINOMA; CANCER GRADING; CANCER STAGING; CARCINOMA; GENETICS; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; PROGNOSIS; TUMOR VOLUME; UROLOGIC NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR BURDEN; UROLOGIC NEOPLASMS; YOUNG ADULT;

EID: 84988969230     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0120-2     Document Type: Article

References (35)

1. Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 Update. Eur Urol. 2011;59(4):584-94.
2. Cummings KB. Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin N Am. 1980;7(3):569-78.
3. Fang D, Zhang L, Li X. Xiong G, Chen X, Han W, er al: Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. J Cancer Res Clin Oncol. 2014;140(3):477-85.
4. Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003;98(8):1620-6.
5. Holmang S, Johansson SL. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol. 2006;175(1):69-72 (discussion 72-3).
6. Novara G, De Marco V, Dalpiaz O, Galfano A, Bouygues V, Gardiman M, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol. 2009;16(2):187-91.
7. Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127-34.
8. Bloom NA, Vidone RA, Lytton B. Primary carcinoma of the ureter: a report of 102 new cases. J Urol. 1970;103(5):590-8.
9. Mufti GR, Gove JR, Badenoch DF, Fowler CG, Tiptaft RC, England HR, et al. Transitional cell carcinoma of the renal pelvis and ureter. Br J Urol. 1989;63(2):135-40.
10. Charbit L, Gendreau MC, Mee S, Cukier J. Tumors of the upper urinary tract: 10 years of experience. J Urol. 1991;146(5):1243-6.
11. Li WM, Shen JT, Li CC, Ke HL, Wei YC, Wu WJ, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol. 2010;57(6):963-9.
12. Krogh J, Kvist E, Rye B. Transitional cell carcinoma of the upper urinary tract: Prognosis variables and post-operative recurrences. Br J Urol. 1991;67(1):32-6.
13. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23(13):2903-10.
14. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61(24):8659-63.
15. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res. 2007;13(24):7296-304.
16. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010;16(23):5842-51.
17. Monteiro-Reis S, Leca L, Almeida M, Antunes L, Monteiro P, Dias PC, et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. European Journal of Cancer. 2014;50(1):226-33.
18. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 1996;10(10):1183-91.
19. Miyata Y, Watanabe S, Kanetake H, Sakai H. Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract. BMC Cancer. 2012;12:372.
20. Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE. Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics. 2010;3:58.
21. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders Elsevier; 2007.
22. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937-44.
23. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB, et al. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821-6.
24. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 2001;61(7):2847-51.
25. Miyake H, Hara I, Kamidono S, Eto H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol. 2004;172(3):1127-9.
26. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet. 1993;342(8879):1087-8.
27. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686-92.
28. Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, et al. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clin Genitourin Cancer. 2012;10(2):114-20.
29. Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis. 2006;27(1):112-6.
30. Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, Cortessis VK, et al. RUNX3 Methylation reveals that Bladder Tumors are Older in Patients with a History of Smoking. Cancer Res. 2008;68(15):6208-14.
31. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K, et al. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology. 2008;75(3-4):145-51.
32. Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, et al. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Cancer Res. 2013;32:94. DOI: 10.1186/1756-9966-32-94.
33. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA. 2007;104(29):12129-34.
34. Cukuranovic R, Ignjatovic I, Visnjic M, Velickovic LJ, Petrovic B, Potic M, et al. Characteristics of upper urothelial carcinoma in an area of Balkan endemic nephropathy in South Serbia. A fifty-year retrospective study. Tumori. 2010;96(5):674-9.
35. Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, et al. Behavior of urothelial carcinoma with respect to anatomical location. J Urol. 2007;177(5):1715-20.